PT  - JOURNAL ARTICLE
AU  - KIM, HYUN JUNG
AU  - HEO, KYUN
TI  - YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation
AID  - 10.21873/anticanres.14818
DP  - 2021 Feb 01
TA  - Anticancer Research
PG  - 671--678
VI  - 41
IP  - 2
4099  - http://ar.iiarjournals.org/content/41/2/671.short
4100  - http://ar.iiarjournals.org/content/41/2/671.full
SO  - Anticancer Res2021 Feb 01; 41
AB  - Background/Aim: Hepatocyte growth factor (HGF) acts as a key regulator in promoting ovarian cancer metastasis. Previously, we observed that YYB-101, a humanized anti-HGF antibody, effectively inhibits ovarian cancer cell migration, invasion, and progression. Here, we evaluated the signaling mechanisms affected by YYB-101 that are important in ovarian cancer cell progression. Materials and Methods: Using cell migration, invasion and proliferation assays, we evaluated the effects of YYB-101 on A2780/luc and SKOV3 cells. The effects of YYB-101 on signaling molecules were determined by immunocytochemistry and immunoblot analysis. Results: YYB-101 inhibited HGF-induced ovarian cancer cell motility by down-regulating paxillin phosphorylation and actin-cytoskeleton rearrangement. Also, YYB-101 inhibited ovarian cancer cell proliferation by reducing c-MET phosphorylation and activating apoptosis in vitro and in vivo. These effects were significantly enhanced by combining YYB-101 treatment with paclitaxel, a standard chemotherapy drug. Conclusion: YYB-101 can be examined as a new therapeutic agent for the treatment of patients with ovarian cancer.